Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioLineRx (BLRX) Common Equity: 2023-2024

Historic Common Equity for BioLineRx (BLRX) over the last 2 years, with Dec 2024 value amounting to $13.5 million.

  • BioLineRx's Common Equity rose 43.57% to $20.1 million in Q2 2025 from the same period last year, while for Jun 2025 it was $20.1 million, marking a year-over-year increase of 43.57%. This contributed to the annual value of $13.5 million for FY2024, which is 1.80% up from last year.
  • Latest data reveals that BioLineRx reported Common Equity of $13.5 million as of FY2024, which was up 1.80% from $13.2 million recorded in FY2023.
  • In the past 5 years, BioLineRx's Common Equity ranged from a high of $13.5 million in FY2024 and a low of $13.2 million during FY2023.
  • Over the past 2 years, BioLineRx's median Common Equity value was $13.3 million (recorded in 2023), while the average stood at $13.3 million.
  • Data for BioLineRx's Common Equity shows a peak YoY rose of 1.80% (in 2024) over the last 5 years.
  • Over the past 2 years, BioLineRx's Common Equity (Yearly) stood at $13.2 million in 2023, then rose by 1.80% to $13.5 million in 2024.